JP2024514101A5 - - Google Patents
Info
- Publication number
- JP2024514101A5 JP2024514101A5 JP2023560806A JP2023560806A JP2024514101A5 JP 2024514101 A5 JP2024514101 A5 JP 2024514101A5 JP 2023560806 A JP2023560806 A JP 2023560806A JP 2023560806 A JP2023560806 A JP 2023560806A JP 2024514101 A5 JP2024514101 A5 JP 2024514101A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- chimeric antigen
- antigen receptor
- cells
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169575P | 2021-04-01 | 2021-04-01 | |
| US63/169,575 | 2021-04-01 | ||
| PCT/US2022/023112 WO2022212879A1 (en) | 2021-04-01 | 2022-04-01 | Il-13ra2 chimeric antigen receptors and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514101A JP2024514101A (ja) | 2024-03-28 |
| JP2024514101A5 true JP2024514101A5 (cg-RX-API-DMAC7.html) | 2025-04-08 |
Family
ID=81384926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560806A Pending JP2024514101A (ja) | 2021-04-01 | 2022-04-01 | Il-13ra2キメラ抗原受容体および使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240189351A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4314069A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514101A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022212879A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4588939A1 (en) * | 2024-01-16 | 2025-07-23 | Universitat de Barcelona | Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3250609A4 (en) * | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
| AU2016332900C1 (en) * | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CA3063695A1 (en) | 2017-05-17 | 2018-11-22 | Seattle Children's Hospital (Dba Seattle Children's Research Institute | Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy |
| BR112020005938A2 (pt) * | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| JP7438123B2 (ja) * | 2018-03-14 | 2024-02-26 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | 腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体 |
| WO2020210665A1 (en) * | 2019-04-12 | 2020-10-15 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with cd20 safety switch |
-
2022
- 2022-04-01 JP JP2023560806A patent/JP2024514101A/ja active Pending
- 2022-04-01 US US18/285,218 patent/US20240189351A1/en active Pending
- 2022-04-01 WO PCT/US2022/023112 patent/WO2022212879A1/en not_active Ceased
- 2022-04-01 EP EP22718479.3A patent/EP4314069A1/en active Pending